Literature DB >> 10715583

Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells.

H Shy1, L Malaiyandi, P S Timiras.   

Abstract

Estrogens influence differentiation, growth and function of neurons, but less is known of their effects on glia. In our experiments reported here, the ovarian steroid, 17beta-estradiol, and the "designer", non-steroidal estrogen, tamoxifen, effectively protected C-6 glioma 2B clone cells from the cytotoxicity of the excitatory neurotransmitter, glutamate. Exposure of these cells to 10-20 mM glutamate induced 61-78% cell death. Pre-treatment of the cells with 0.01 mM estradiol or with 2 microM tamoxifen significantly reduced the glutamate-induced cell death, estradiol being the most effective in this regard. Estradiol- or tamoxifen-treated cells that had survived glutamate damage appeared more mature than controls. Thus, estrogens often used in therapy (estradiol as replacement after menopause and tamoxifen for treatment/prevention of breast cancer) may significantly protect glial cells against glutamate toxicity and stimulate cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10715583     DOI: 10.1016/s0736-5748(99)00097-0

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  10 in total

1.  Effects of toxic doses of glutamate on Cu-Zn and Mn/superoxide dismutases activities in human glioma cell lines.

Authors:  Andrea Regner; Daniel Pretto Schunemann; Ivana Grivicich; Celito Luis Diel; Caroline Brunetto Farias; Giovana Kowaleski; Edlaine Mondadori; Gilberto Schwartsmann; Adriana Brondani da Rocha
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  Characteristics of adverse events of endocrine therapies among older patients with breast cancer.

Authors:  Naoko Honma; Masujiro Makita; Shigehira Saji; Tetuo Mikami; Hideaki Ogata; Rie Horii; Futoshi Akiyama; Takuji Iwase; Shinji Ohno
Journal:  Support Care Cancer       Date:  2019-02-07       Impact factor: 3.603

Review 3.  Estrogen and selective estrogen receptor modulators: neuroprotection in the Women's Health Initiative era.

Authors:  Stephanie Murphy; Louise McCullough; Marguerite Littleton-Kearney; Patricia Hurn
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 4.  Targeting estrogen receptors for the treatment of Alzheimer's disease.

Authors:  Jung Hoon Lee; Yanxialei Jiang; Dong Hoon Han; Seung Kyun Shin; Won Hoon Choi; Min Jae Lee
Journal:  Mol Neurobiol       Date:  2013-06-16       Impact factor: 5.590

5.  Cytoprotective effect of estrogen on ammonium chloride-treated C6-glioma cells.

Authors:  N Haghighat; M M Oblinger; D W McCandless
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

Review 6.  Molecular bases of methamphetamine-induced neurodegeneration.

Authors:  Jean Lud Cadet; Irina N Krasnova
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

7.  Deficits in synaptic function occur at medial perforant path-dentate granule cell synapses prior to Schaffer collateral-CA1 pyramidal cell synapses in the novel TgF344-Alzheimer's Disease Rat Model.

Authors:  Lindsey A Smith; Lori L McMahon
Journal:  Neurobiol Dis       Date:  2017-12-01       Impact factor: 5.996

8.  Cancer risk among parous women following assisted reproductive technology.

Authors:  M M Reigstad; I K Larsen; T Å Myklebust; T E Robsahm; N B Oldereid; A K Omland; S Vangen; L A Brinton; R Storeng
Journal:  Hum Reprod       Date:  2015-06-24       Impact factor: 6.918

9.  Parity, age at first birth, and risk of death from brain cancer: a population-based cohort study in Taiwan.

Authors:  Hui-Fen Chiu; Chih-Cheng Chen; Shang-Shyue Tsai; Shu-Chen Ho; Chun-Yuh Yang
Journal:  BMC Public Health       Date:  2012-10-09       Impact factor: 3.295

10.  Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells.

Authors:  A González; C Martínez-Campa; M D Mediavilla; C Alonso-González; E J Sánchez-Barceló; S Cos
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.